Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.

ABSTRACT:

Background

Anaplastic lymphoma kinase-positive (ALK+) and ROS proto-oncogene 1 (ROS1)-positive (ROS1+) lung cancers have been reported to be associated with an elevated risk of thromboembolic events. This study aimed to assess the long-term risk of developing thromboembolism (TE) in ROS1+ lung cancer and to compare it with other oncogenic drivers in the Asian population.

Materials and methods

We retrospectively enrolled a cohort of ROS1+ lung adenocarcinoma in a medical center in Taiwan and a comparison cohort of ALK+ and epidermal growth factor receptor-positive (EGFR+) lung cancers. Venous and arterial TEs were identified throughout the cancer course, and the incidence rate was calculated.

Results

We enrolled 44 ROS1+, 98 ALK+, and 168 EGFR+ non-small-cell lung canc

SUBMITTER: Wang HY 

PROVIDER: S-EPMC9808475 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature